注册号:

Registration number:

ITMCTR2025000835

最近更新日期:

Date of Last Refreshed on:

2025-04-24

注册时间:

Date of Registration:

2025-04-24

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

Public title:

Retrospective Analysis of a Pilot Quasi-Experimental Study on Novel Herbal Formula for Minor Depression

注册题目简写:

English Acronym:

Novel Herbal Formula for Minor Depression

研究课题的正式科学名称:

Scientific title:

Retrospective Analysis of a Pilot Quasi-Experimental Study on Novel Herbal Formula for Minor Depression

研究课题的正式科学名称简写:

Scientific title acronym:

Novel Herbal Formula for Minor Depression

研究课题代号(代码):

Study subject ID:

nil

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

nil ;

申请注册联系人:

研究负责人:

Applicant:

Tang Hiu To

Study leader:

Dr. YU Jucheng Danny

申请注册联系人电话:

Applicant telephone:

34112966

研究负责人电话:

Study leader's telephone:

34115309

申请注册联系人传真 :

Applicant Fax:

nil

研究负责人传真:

Study leader's fax:

nil

申请注册联系人电子邮件:

Applicant E-mail:

22482415@life.hkbu.edu.hk

研究负责人电子邮件:

Study leader's E-mail:

dannyu@hkbu.edu.hk

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

nil

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

nil

申请注册联系人通讯地址:

研究负责人通讯地址:

Applicant address:

Rm 515. 5/F. David C.Lam Building. 34 Renfrew Road. Hong Kong Baptist University. Kowloon Tong Kowloon

Study leader's address:

Rm 515. 5/F. David C.Lam Building. 34 Renfrew Road. Hong Kong Baptist University. Kowloon Tong Kowloon

申请注册联系人邮政编码:

Applicant postcode:

000

研究负责人邮政编码:

Study leader's postcode:

000

申请人所在单位:

Applicant's institution:

Hong Kong Baptist University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

REC/23-24/0553

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

Name of the ethic committee:

Hong Kong Baptist University Research Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2024/9/11 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

Mr. Carter Cheung

伦理委员会联系地址:

Contact Address of the ethic committee:

Hong Kong Baptist University. Kowloon Tong. Kowloon. Hong Kong

伦理委员会联系人电话:

Contact phone of the ethic committee:

34117941

伦理委员会联系人邮箱:

Contact email of the ethic committee:

hkbu_rec@hkbu.edu.hk

研究实施负责(组长)单位:

Primary sponsor:

The Hong Kong Jockey Club Charities Trust

研究实施负责(组长)单位地址:

Primary sponsor's address:

13/F. Jockey Club Headquarters. 1 Sports Road Happy Valley. Hong Kong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

省(直辖市):

市(区县):

Country:

China

Province:

Hong Kong

City:

单位(医院):

具体地址:

Institution
hospital:

Vincent and Lily Woo Foundation

Address:

Hong Kong Baptist University Kowloon Tong Kowloon

国家:

省(直辖市):

市(区县):

Country:

China

Province:

Hong Kong

City:

单位(医院):

具体地址:

Institution
hospital:

Hong Kong Baptist University

Address:

Hong Kong Baptist University Kowloon Tong Kowloon

经费或物资来源:

Source(s) of funding:

The Hong Kong Jockey Club Charities Trust

研究疾病:

研究疾病代码:

Target disease:

Depressive Episode with Insufficient Symptoms

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

病例研究

Case study

研究所处阶段:

Study phase:

回顾性研究

Retrospective study

研究目的:

Objectives of Study:

This real-world study aimed to evaluate the transdiagnostic effects and safety of a Chinese herbal formula on improving sleep and mood in adults with a depressive episode with insufficient symptoms and explored the factors associated with a favorable treatment response.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

Participants received a 7-day supply of Chinese herbal formula at each weekly visit for four weeks. The core herbs in the herbal formula included Curcumae Radix (Yujin) Paeoniae Radix Alba (Baishao) Triticum Aestivum (Fuxiaomai) and Acanthopanacis Senticosi Radix et Rhizoma Sue Caulis (Ciwujia). The herbs were supplied by Tianjiang Pharmaceutical Co. Ltd. Adjustment of up to two herbs was allowed per visit depending on the individuals constitution and symptoms which aligns with real-world personalized clinical practice.

纳入标准:

Inclusion criteria

1) Age between 18 and 65; 2) Report the presence of 2 to 4 criterion symptoms of depression for 2 weeks or longer with at least 1 of the core symptoms (depressed mood or anhedonia); 3) Score between 5-14 in PHQ-9 in screening and baseline assessment; 4) Understand and be able to follow written and oral instructions in Chinese to complete the assessment questionnaire; 5) Willing and able to provide informed consent.

排除标准:

Exclusion criteria:

1) Major Depressive Disorder (MDD) episode in past 6 months; 2) Present with severe symptoms of depression as indicated by PHQ-9 score >14; 3) History of active alcohol and/or substance abuse disorder in the past 12 months or history of psychiatric or psychotic disorders such as mania schizophrenia bipolar disorder post-traumatic stress disorder or obsessive-compulsive disorder; 4) History of major neurologic disorder (e.g. Parkinson disease Alzheimer disease or other dementia brain tumor seizure disorder or delirium episode); 5)Conditions that could make it difficult to conclusively determine that depressive symptoms were the result in some other conditions; 6)Current active suicidal or self-injurious potential necessitating immediate treatment; 7) History of serious chronic illness such as cancer stroke heart diseases end-stage liver and kidney diseases. 8) Pregnancy or lactation female; 9) Currently undergoing prescribed psychotropic medication psychotherapy or TCM treatment; 10) undergoing electroconvulsive therapy (ECT) in the past 12 months; 11) any psychiatric hospitalization in the past 2 years; 12) Allergic history to Chinese herbal drugs; 13) Concurrent participation in other clinical trials.

研究实施时间:

Study execute time:

From 2024-09-11

To      2025-01-31

征募观察对象时间:

Recruiting time:

From 2024-09-11

To      2024-10-11

干预措施:

Interventions:

组别:

样本量:

67

Group:

intervention group

Sample size:

干预措施:

干预措施代码:

DEP-2306

Intervention:

Chinese herbal formula

Intervention code:

样本总量 Total sample size : 67

研究实施地点:

Countries of recruitment
and research settings:

国家:

省(直辖市):

市(区县):

Country:

China

Province:

Hong Kong

City:

单位(医院):

单位级别:

Institution/hospital:

Hong Kong Baptist University (HKBU) Mr. & Mrs. Chan Hon Yin Chinese Medicine Specialty Clinic and Good Clinical Practice Centre

Level of the institution:

Clinic

测量指标:

Outcomes:

指标中文名:

指标类型:

次要指标

Outcome:

Pittsburgh Sleep Quality Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

W0 W1 W2 W3 W4

Measure method:

self-rated questionnaire

指标中文名:

指标类型:

次要指标

Outcome:

Hamilton depression rating scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

W0 W2 W4

Measure method:

clinician-rated questionnaire

指标中文名:

指标类型:

次要指标

Outcome:

General Anxiety Disorder-7

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

W0 W1 W2 W3 W4

Measure method:

self-rated questionnaire

指标中文名:

指标类型:

次要指标

Outcome:

Compliance rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

W0 W1 W2 W3 W4

Measure method:

clinician-rated

指标中文名:

指标类型:

次要指标

Outcome:

Perceived Stress Scale-10

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

W0 W1 W2 W3 W4

Measure method:

self-rated questionnaire

指标中文名:

指标类型:

主要指标

Outcome:

Patient Health Questionnaire-9

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

W0 W1 W2 W3 W4

Measure method:

self-rated questionnaire

指标中文名:

指标类型:

次要指标

Outcome:

Adverse events

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

W0 W1 W2 W3 W4

Measure method:

clinician-rated

指标中文名:

指标类型:

次要指标

Outcome:

Brief Resilience Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

W0 W1 W2 W3 W4

Measure method:

self-rated questionnaire

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

结束

Completed

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

nil

盲法:

Blinding:

nil

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The study protocol, statistical analysis plan, and all de-identified data supporting the findings will be made available for sharing three years after publication. Interested researchers should provide proposals to Dr. Danny Yu via dannyu@hkbu.edu.hk and sign a data access agreement.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

RedCap

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统